TY - JOUR T1 - EPV149/#132 Performance characteristics of brief family history questionnaire to screen for lynch syndrome in women with newly diagnosed ovarian cancers JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - A89 LP - A89 DO - 10.1136/ijgc-2021-IGCS.219 VL - 31 IS - Suppl 4 AU - RS Kim AU - A Tone AU - R Kim AU - M Cesari AU - L Eiriksson AU - T Hart AU - A Lytwyn AU - M Maganti AU - M Bernardini AU - A Oza AU - B Djordjevic AU - J Lerner-Ellis AU - E Van De Laar AU - D Vicus AU - A Pollett AU - S Ferguson Y1 - 2021/11/01 UR - http://ijgc.bmj.com/content/31/Suppl_4/A89.1.abstract N2 - Objectives Ovarian cancer (OC) is the third most common Lynch syndrome (LS)-associated cancer in women but there is no established screening strategy to identify LS in this population. We have previously validated the 4-item brief Family History Questionnaire (bFHQ) in endometrial cancers. The objective of this study was to assess whether bFHQ can be used as a screening tool to identify women with OC at risk of LS.Methods In this multicenter prospective cohort study, women with OC completed bHFQ, extended Family History Questionnaire (eFHQ; encompassing Amsterdam II criteria, Society of Gynecologic Oncology 20–25% criteria and Ontario Ministry of Health criteria), immunohistochemistry (IHC) for mismatch repair (MMR) proteins and universal germline testing for LS. Performance characteristics were compared between bFHQ, eFHQ, and IHC.Results of 215 participants, 169 (79%) were evaluable with both bFHQ and germline mutation status; 12 of these 169 were confirmed to have LS (7%). Nine of 12 patients (75%) with LS were correctly identified by bFHQ, compared to 6 of 11 (55%) by eFHQ and 11 of 13 (85%) by IHC. The sensitivity, specificity, positive predictive values and negative predictive values of bFHQ were 75%, 66%, 15% and 98%. The 4-item bFHQ was more sensitive than eFHQ and took less than 10 minutes for each patient to complete.Conclusions Patient-administered bFHQ may serve as an adequate screening tool to triage women with OC for further genetic assessment for LS, especially in centers without access to universal tumor testing for IHC for MMR. ER -